Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure
Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure
复制标题
DOI：
10.1111/imj.12283
复制
发表时间：
2013-11-01
影响因子：
2.1
通讯作者：
Kanjanapan, Y.
中科院分区：
文献类型：
--
作者：
Farinola, N.;Kanjanapan, Y.
Denosumab是一种用于骨质疏松症和实体瘤骨骼转移的抗吸收治疗药物，可导致低钙血症。由于不同的血钙临界值和测量时间，其发生率可能高于先前报道。以下病例说明了尽管补充了钙，但仍有低钙血症风险的患者。这些人群，由于转移性骨病或继发性甲状旁腺功能亢进引起的潜在高骨转换，可能需要在denosumab给药后更密切地监测钙水平。
Denosumab, an anti-resorptive treatment for osteoporosis and skeletal metastases from solid tumours, can cause hypocalcaemia. The incidence may be higher than previously reported due to varying serum calcium cut-off and timing of measurement. The following cases illustrate patients at risk of hypocalcaemia despite supplementation. These populations, with underlying high bone turnover from metastatic bone disease or secondary hyperparathyroidism due to renal failure, may require closer monitoring of calcium levels post-denosumab administration.